# OnCo record trilynx (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/trilynx/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "trilynx", "NCT04459715" ;
  schema:name "TrilynX"@en ;
  schema:description "TrilynX tested xevinapant, a drug meant to make tumours more sensitive to radiation, with cisplatin chemoradiation in 730 patients with locally advanced head and neck cancer. Despite a striking phase 2 result, the phase 3 was stopped for futility in 2024 with worse outcomes on xevinapant, a reminder that early wins in this disease often do not replicate."@en ;
  schema:url <https://onco.cc/trials/trilynx/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04459715>, <https://ascopubs.org/doi/10.1200/JCO-25-00272> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:phase-2-to-3-attrition" ;
  onco:phase "3" ;
  schema:startDate "2020-08-07" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/xevinapant/> ;
  onco:companies <https://onco.cc/companies/debiopharm/> .